17 Sep 09
Hardly a day goes by without a new report, today AT Kearney, last week Roland Berger and before them IMS and PWC warning of a gloomy future for pharmaceutical companies and saying that they must change their ways.
Paul Dixey, Managing Partner, BlueLight Partners
16 Sep 09
More than half of schizophrenia patients are expected to relapse within two years if untreated and 4 out of 5 within five years, according to experts. Antipsychotics can reduce the relapse rate so long as patients continue on treatment. However, adherence is notoriously poor. A new antippsychotic – asenapine – shows promise of being effective and better tolerated.
Olwen Glynn Owen
11 Aug 09
As Capitol Hill readies itself for the August Recess, and as President Barack Obama demands that a bill reach his desk in the Oval Office by October, healthcare reform still finds itself in more-or-less the same quagmire as it did in 1993. We take a look at the chances of comprehensive reform this year and tackle the nitty-gritty of one of the most complex and polarising issues of Washington politics today.
15 Jul 09
With increased investment in R&D largely failing to fill drug development pipelines, the pharma industry is looking to get more bang for its R&D buck by generating some return out of failed drug candidates and extra return out of others. Drug re-positioning has become a key strategy for pharmaceutical groups, and according to Datamonitor, this approach is set to become more frequently employed.
02 Jul 09
Getting a job in Clinical research or Regulatory Affairs can be tough at the best of times. Have you ever wondered how some people seem to know everybody and they are always the first to know what is happening in the industry and what roles are available?
01 Jul 09
Spanning one third of the globe's circumference and home to more than half of the world's population, the Asia Pacific region is incredibly diverse. This year's World Vaccine Congress Asia highlighted the enormous variation in the vaccine landscape in the region, owing to a myriad of political, cultural, economic and geographic differences.
18 Jun 09
Field reporter Rhonda Siddall reports from EULAR
Rhonda Siddall - Pharmiweb Field Reporter
15 Jun 09
Unless it paints the right picture you’re letting the side down!
In a depressed job market, an employer is likely to receive 50+ CVs per job advertised from 5 or more Preferred Agencies and many more from agencies who ‘piggy back’ in. So now, more than ever, your CV needs to stand out and be tailored to the role and client and submitted by an agency with valid access.
Avril Horn PhD
12 Jun 09
Datamonitor attended the American Society of Clinical Oncology's 45th Annual Meeting in Orlando, Florida, to assess the key highlights of the conference. A number of promising presentations evaluated the potential of currently marketed agents to successfully combine with conventional chemotherapy in indications with persistent high unmet needs.
11 Jun 09
Dr Wolfgang Wein, Executive Vice-President of Merck Serono’s Oncology Business comments on the recent final appraisal determination by NICE paving the way for its leading oncology product Erbitux to benefit UK mCRC patients.
Olwen Glynn Owen - Pharmiweb Field reporter
05 Jun 09
Despite the pharmaceutical industry's evolving business model in response to growing regulatory constraints, the sector is facing unprecedented challenges caused by the economic downturn and President Obama's planned overhaul of the US healthcare system. To continue on its journey towards 'Pharma 2.0', the industry must balance the more pressing short term issues against longer term trends
Priyanka Adhikari - Datamonitor
01 Jun 09
The Department of Health is determined to improve commissioning, and it will do whatever it takes to make it happen. That is the message that senior departmental officials sent to practice based commissioners last week at a National Association of Primary Care conference in London.
01 Jun 09
The time has arrived for primary care trusts to shed their provider functions, and it is causing considerable angst in the community services sector. It was inevitable that sooner or later, the split would have to happen, but now the race is on to decide what organisation model they want to adopt: foundation trust or social enterprise?
20 May 09
Senior Department of Health executives, speaking at a recent NHS Alliance Conference, suggested that the NHS has two years left before it starts to the credit crunch’s bite – maybe less if there is an election in a years’ time. But this should not be cause complacency in the health sector. The message is, invest wisely now so that you are well prepared for the fallow times ahead.
18 May 09
The growing incidence of diseases and conditions related to aging is creating pockets of opportunity for pain management. These opportunities include the expanding use of prescription NSAIDs as second-line therapies for chronic pain and an increase in off-label prescribing. As populations and indications evolve, so too is the pain management sector.
Applied Data Research
14 May 09
In this edition of StrategicEdge, CBR Pharma Insights discusses the current trends and opportunities that exist in marketing to consumers as the age of TiVo, DVRs, and cost constraints point the industry towards creative uses of the internet and other e-technologies.
CBR Pharma Insights
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.